Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's SFDA Sets New GMP Inspectional Guidelines

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's State Food and Drug Administration issued revised good manufacturing practice inspectional guidelines Oct. 24 in an effort to increase quality systems standards for pharmaceutical manufacturers. The new guidelines are scheduled to go into effect Jan. 1, replacing the current GMP inspectional guidelines, which were implemented in 1998

You may also be interested in...



Benda’s Jiangling Plant Gets Production Approval

SHANGHAI - Benda's Jiangling plant has received approval from China's State FDA for the production of active pharmaceutical ingredients, the company announced Jan. 22

Benda’s Jiangling Plant Gets Production Approval

SHANGHAI - Benda's Jiangling plant has received approval from China's State FDA for the production of active pharmaceutical ingredients, the company announced Jan. 22

Sidley Austin Beijing Senior Counsel Chen Yang: An Interview with PharmAsia News

Chen Yang, senior counsel in Sidley Austin's Beijing office, recently spoke with PharmAsia News about recent developments in China that affect the pharmaceutical and medical device industries. Yang leads the firm's China life sciences practice. For the past 10 years, she has advised international companies on their investment projects and acquisition efforts in various Chinese industries and provided regulatory advice on intellectual property, life science, employment and other issues. She has also assisted China government agencies in several U.S. litigation matters.

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel